Compare Recursion Pharmaceuticals Inc (RXRX) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United Airlines Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while United Airlines Holdings Inc trades at $107.36 (market cap $34.77B). The key difference: United Airlines Holdings Inc is far larger — about 20× Recursion Pharmaceuticals Inc's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | UAL | |
|---|---|---|
Market Cap | $1.74B | $34.77B |
Sector | Health | Industrials |
52-Week High | $6.79 | $136.11 |
52-Week Low | $2.84 | $85.21 |
Enterprise Value | $1.26B | $51.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
United Airlines (UAL) trades at $108.24, down 2.82% today, with a bearish technical signal but strong fundamentals including a P/E of 10.13 and net income margin of 5.56%. Recent earnings beats and a major international expansion announced in August 2026 highlight growth potential, though cash flow turned negative in 2025 due to capital investments.
The outlook is positive with a consensus price target of $168.96 (56% upside), supported by 66% analyst buy ratings. Risks include high jet fuel costs and geopolitical tensions, but robust travel demand and efficient operations position UAL for recovery if macroeconomic pressures ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
